Tirzepatide (Mounjaro, Zepbound) targets two pathways (GLP-1 and GIP), producing greater weight loss in head-to-head studiesroughly 20% body weight loss on tirzepatide vs 15% on semaglutide
Contraindications Because no GLP-1 patches have been approved, there are no official contraindications for this form
Microdosing may be an option for many people, but you should always talk with your provider before changing your dose
It is also used to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and known heart disease
His patients receive constant medical oversight, progress tracking, and education about nutrition and behavioral habits
Individuals on a GLP-1 receptor drug reported the following: 65% reported nausea, compared to 16% of placebo 37% reported abdominal pain, compared to 6% of placebo